On December 15, 2025, China’s National Medical Products Administration officially approved the market launch of the new anti-cancer drug zurletrectinib (ICP-723). This milestone breakthrough brings unprecedented therapeutic hope to patients worldwide with solid tumors harboring NTRK fusion genes.
**Revolutionary “Tumor-Agnostic” Therapy: The Scientific Breakthrough of Zurletrectinib**
Zurletrectinib is China’s first independently developed new-generation TRK inhibitor, specifically designed for patients with locally advanced or metastatic solid tumors harboring Neurotrophic Tyrosine Receptor Kinase (NTRK) fusion genes. This “tumor-agnostic” broad-spectrum anticancer drug represents a paradigm shift in the field of oncology treatment—transitioning from traditional site-of-origin-based classification and treatment to precision targeted therapy based on genetic alterations.
**Key Indications:**
* Patients diagnosed via fully validated testing as carrying an NTRK fusion gene (excluding known acquired resistance mutations).
* Adult and adolescent patients (12 years and older) with solid tumors who have no satisfactory alternative treatment or whose prior treatments have failed.
**Core Advantage:**
As long as an NTRK fusion gene is detected through genetic testing, patients may potentially benefit significantly from zurletrectinib treatment, regardless of whether the tumor originated in the lung, thyroid, breast, colon, or other sites.
**Outstanding Clinical Data: Redefining Treatment Expectations**
Clinical trials of zurletrectinib conducted in China have demonstrated impressive efficacy data, offering substantial survival hope for patients with advanced solid tumors:
* **Overall Response Rate (ORR): 89.1%** — Nearly 90% of patients experienced significant tumor shrinkage.
* **Disease Control Rate (DCR): 96.4%** — Disease progression was effectively controlled in almost all patients.
* **24-month Progression-Free Survival (PFS) Rate: 77.4%** — Long-term control of disease progression.
* **24-month Overall Survival (OS) Rate: 90.8%** — Significantly prolonged patient survival time.
**Beijing South Region Oncology Hospital International Department: Your Gateway to Cutting-Edge Cancer Treatment**
Beijing South Region Oncology Hospital International Department is committed to providing global patients with access to advanced cancer treatment solutions. Our international medical team is dedicated to offering comprehensive, personalized medical support for every international patient.
Our specialized services include:
1. International patient treatment consultation and evaluation.
2. Arrangement and interpretation of NTRK fusion gene testing.
3. Multidisciplinary expert consultation and comprehensive treatment planning.
4. Multilingual medical translation and cultural adaptation support.
**Contact Beijing South Region Oncology Hospital International Department**
We understand the complexities and challenges international patients face when seeking medical care abroad. Therefore, we have established convenient and diverse communication channels to ensure you can easily access authoritative medical information and initiate the treatment process.
**Preferred Contact Method:**
* International Patient Hotline: 400-880-3716
**Diverse Contact Channels:**
* WeChat Consultation: Add ID “17801183037″ for message-based consultation and quick responses.
* Email Consultation:
* General Inquiry: 100085_010@163.com
* International Medical Exclusive: myimmnet@163.com
**International Patient Process:**
1. Contact our International Patient Coordinator through any of the above channels.
2. Submit medical records for preliminary assessment (including pathology reports, genetic test results, etc.).
3. Schedule a remote video consultation with an international oncology expert.
4. If treatment in China is required, we will assist with medical visa processing, accommodation arrangements, and other logistics.
5. Enjoy one-stop medical services upon arrival in Beijing, from airport pickup to the entire treatment journey.
**Important Reminder: Pre-Treatment Genetic Testing is Crucial**
As a targeted drug, the efficacy of zurletrectinib highly depends on accurate genetic testing. We recommend that all patients considering this therapy first undergo NTRK fusion gene testing. Beijing South Region Oncology Hospital International Department can arrange internationally recognized testing services for you or provide authoritative interpretation of your existing test results.
**Looking Ahead: A New Era of Personalized Cancer Treatment**
The approval of zurletrectinib is not just the launch of a new drug; it is a powerful testament to China’s capabilities in precision cancer therapy. Beijing South Region Oncology Hospital International Department will continue to follow global advancements in cancer treatment, integrate high-quality medical resources from both domestic and international sources, and provide world-class, patient-centered cancer diagnosis and treatment services for international patients.
**Call now to inquire whether you or your loved one is a candidate for this innovative therapy!**
Beijing South Region Oncology Hospital International Department International Patient Hotline: 400-880-3716
WeChat ID: 17801183037
Email: 100085_010@163.com; myimmnet@163.com
**Note:** The medical information in this article is based on publicly available clinical trial data. Specific treatment plans must be formulated by professional physicians based on individual patient circumstances. It is recommended that all patients consult qualified healthcare professionals before considering any treatment.
Post time: Dec-31-2025